31
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Common risk factors for heart failure and cancer

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cardiovascular (CV) disease and cancer are the leading causes of death. 1 , 2 Over the last decades, it has been appreciated that both CV disease and cancer are more common in individuals in whom risk factors for disease development accumulate, and preventative measures have been extremely important in driving down the incidence of disease. 3–6 In general, the field of epidemiology, risk reduction, and preventative trials is divided into health care professionals who have an interest in either CV disease or cancer. As a result, the medical literature and medical practice has largely focused on the one disease, or the other. However, human individuals do not behave according to this dogma. Emerging data clearly suggest that identical risk factors may lead to CV disease in the one individual, but may cause cancer in another, or even both diseases in the same individual. This overlap exists between risk factors that are historically classified as ‘CV risk factors’ as these factors do equally strong predict cancer development. Therefore, we propose that a holistic approach might better estimate actual risks for CV disease and cancer. In this review, we summarize current insights in common behavioural risk factors for heart failure, being the most progressed and lethal form of CV disease, and cancer.

          Related collections

          Most cited references133

          • Record: found
          • Abstract: found
          • Article: not found

          The blockade of immune checkpoints in cancer immunotherapy.

          Among the most promising approaches to activating therapeutic antitumour immunity is the blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. It is now clear that tumours co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumour antigens. Because many of the immune checkpoints are initiated by ligand-receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutics to achieve US Food and Drug Administration (FDA) approval. Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

                Bookmark

                Author and article information

                Journal
                Cardiovasc Res
                Cardiovasc. Res
                cardiovascres
                Cardiovascular Research
                Oxford University Press
                0008-6363
                1755-3245
                15 April 2019
                04 February 2019
                04 February 2019
                : 115
                : 5 , Spotlight Issue on Cardio-oncology
                : 844-853
                Affiliations
                University Medical Centre Groningen, University of Groningen, Department of Cardiology, Hanzeplein 1, Groningen, The Netherlands
                Author notes
                Corresponding author. Tel: +31 50 3612355; fax: +31 50 3615525, E-mail: r.a.de.boer@ 123456umcg.nl
                Article
                cvz035
                10.1093/cvr/cvz035
                6452432
                30715247
                90266684-6175-43e4-abab-2f88c0a103d6
                © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                : 04 December 2018
                : 29 January 2019
                : 01 February 2019
                Page count
                Pages: 10
                Funding
                Funded by: Netherlands Heart Foundation
                Funded by: CVON DOSIS
                Award ID: 2014-40
                Funded by: CVON SHE-PREDICTS-HF
                Funded by: CVON RED-CVD
                Award ID: 2017-11
                Funded by: Innovational Research Incentives Scheme
                Funded by: Netherlands Organization for Scientific Research
                Funded by: NWO VIDI
                Award ID: 917.13.350
                Funded by: European Research Council 10.13039/100010663
                Award ID: ERC CoG 818715
                Categories
                Invited Spotlight Reviews
                Common Risk Factors in Cardiovascular Disease and Cancer

                Cardiovascular Medicine
                cardio-oncology,heart failure,risk factors,cardiovascular risk factors,hypertension,lipids,biomarkers,inflammation

                Comments

                Comment on this article